Your browser doesn't support javascript.
loading
Advances in studies of cognition enhancement by phosphodiesterase-4 inhibitor roflumilast / 中国药理学与毒理学杂志
Chinese Journal of Pharmacology and Toxicology ; (6): 614-620, 2020.
Article in Chinese | WPRIM | ID: wpr-857514
ABSTRACT
Roflumilast, one of the second generation of phosphodiesterase-4 inhibitors, has been approved for the treatment of severe chronic obstructive pulmonary disease by the United States Food and Drug Administration since 2011. It has shown a variety of beneficial effects, including anti-inflammatory, anti-tumor, anti-alcoholic, and anti-diabetic profiles. Recent studies have demonstrated that roflumilast, like other PDE4 inhibitors, has neuroprotective and precognitive properties. It also has been shown to produce promising cognitive improvement in animals and humans. Therefore, roflumilast can be a potential drug for treatment of various degenerative diseases of the central nervous system, including Alzheimer disease and Parkinson disease. The major mechanism is the activation of cyclic AMP signaling and its downstream targeting molecules. All these are discussed and summarized in the current review.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Chinese Journal of Pharmacology and Toxicology Year: 2020 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Chinese Journal of Pharmacology and Toxicology Year: 2020 Type: Article